S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Celularity (CELU) Competitors

$3.21
-0.10 (-3.02%)
(As of 04/18/2024 ET)

CELU vs. IMMX, RLYB, LABP, MRNS, KRON, EQ, CARM, LTRN, CRVS, and CUE

Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Immix Biopharma (IMMX), Rallybio (RLYB), Landos Biopharma (LABP), Marinus Pharmaceuticals (MRNS), Kronos Bio (KRON), Equillium (EQ), Carisma Therapeutics (CARM), Lantern Pharma (LTRN), Corvus Pharmaceuticals (CRVS), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical preparations" industry.

Celularity vs.

Immix Biopharma (NASDAQ:IMMX) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

In the previous week, Celularity had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Celularity and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.32 beat Celularity's score of 0.00 indicating that Celularity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immix Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Celularity
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immix Biopharma currently has a consensus price target of $14.00, suggesting a potential upside of 460.00%. Given Celularity's higher possible upside, analysts clearly believe Immix Biopharma is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Celularity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Celularity has higher revenue and earnings than Immix Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$15.43M-$0.89-2.83
Celularity$17.98M3.54$14.19MN/AN/A

Celularity received 4 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 42.11% of users gave Celularity an outperform vote.

CompanyUnderperformOutperform
Immix BiopharmaOutperform Votes
4
100.00%
Underperform Votes
No Votes
CelularityOutperform Votes
8
42.11%
Underperform Votes
11
57.89%

Immix Biopharma has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.

11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 55.9% of Immix Biopharma shares are held by insiders. Comparatively, 20.7% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immix Biopharma has a net margin of 0.00% compared to Immix Biopharma's net margin of -1,226.72%. Immix Biopharma's return on equity of 30.79% beat Celularity's return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -101.56% -86.70%
Celularity -1,226.72%30.79%13.28%

Summary

Celularity beats Immix Biopharma on 9 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELU vs. The Competition

MetricCelularityPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$63.57M$6.16B$4.75B$7.40B
Dividend YieldN/A2.97%2.98%3.99%
P/E RatioN/A7.16179.8314.20
Price / Sales3.54315.022,531.4187.29
Price / Cash1.9130.2046.7835.01
Price / Book0.255.384.604.18
Net Income$14.19M$135.74M$102.69M$211.98M
7 Day Performance-29.46%-7.69%-5.05%-4.74%
1 Month Performance-41.43%-6.79%-4.62%-3.29%
1 Year Performance-56.06%-2.61%10.07%4.49%

Celularity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMX
Immix Biopharma
1.0336 of 5 stars
$2.57
-3.4%
$14.00
+444.7%
+44.5%$67.85MN/A-2.8914News Coverage
RLYB
Rallybio
2.1229 of 5 stars
$1.80
-1.6%
$12.20
+577.8%
-60.0%$68.06MN/A-0.9843Analyst Report
Analyst Revision
News Coverage
Gap Up
LABP
Landos Biopharma
0.3356 of 5 stars
$21.51
-0.3%
$20.42
-5.1%
+644.4%$67.11M$18M-6.2219
MRNS
Marinus Pharmaceuticals
4.1937 of 5 stars
$1.20
-7.7%
$18.21
+1,417.9%
-82.0%$65.92M$30.99M-0.46165Analyst Report
Analyst Revision
News Coverage
High Trading Volume
KRON
Kronos Bio
3.1506 of 5 stars
$1.09
-4.4%
$4.25
+289.9%
-23.5%$65.51M$6.29M-0.5662Positive News
EQ
Equillium
1.0354 of 5 stars
$1.85
+4.5%
$3.90
+110.8%
+143.7%$65.22M$36.08M-4.7444Positive News
CARM
Carisma Therapeutics
1.3988 of 5 stars
$1.70
-3.4%
$8.80
+417.6%
-57.9%$70.62M$14.92M-0.49N/A
LTRN
Lantern Pharma
0.1731 of 5 stars
$6.00
+0.5%
N/A+19.8%$64.44MN/A-4.0521Gap Down
CRVS
Corvus Pharmaceuticals
2.7358 of 5 stars
$1.47
flat
$6.63
+350.7%
+22.5%$72.09MN/A-2.5828Short Interest ↓
News Coverage
Positive News
Gap Down
CUE
Cue Biopharma
3.1969 of 5 stars
$1.50
-6.3%
$8.00
+435.1%
-52.1%$72.72M$5.49M-1.3653

Related Companies and Tools

This page (NASDAQ:CELU) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners